Image Attributions

Figure 2.1  (Figure 1) by Raquel Guillamat-Prats is used under a CC-BY 4.0 license.

Figure 2.4 (Fig 1) by Osamu Kumano, Kohei Akatsuchi, Jean Amiral is used under a CC-BY 4.0 license.

Figure 3.2 (Fig 2) by Stamatios Lampsas, Maria Xenou, Evangelos Oikonomou, Panteleimon Pantelidis, Antonios Lysandrou, Savvas Sarantos, Athina Goliopoulou, Konstantinos Kalogera, Vasiliki Tsigkou, Athanasios Kalpis, Stavroula A. Paschou, Panagiotis Theofilis, Manolis Vavuranakis, Dimitris Tousoulis, Gerasimos Siasos is used under a CC-BY 4.0 license.

Figure 3.3 (Fig 1) by Hayato Tada, Atsushi Nohara and Masa-aki Kawashiri is used under a CC-BY 4.0 license.

Figure 3.4 (Fig 1) by Dragos Cretoiu, Ruxandra Florentina Ionescu, Robert Mihai Enache, Sanda Maria Cretoiu  and Silviu Cristian Voinea is used under a CC-BY 4.0 license.

Figure 3.5 (Fig 1) by Simona Pisanti, Erika Rimondi, Elena Pozza, Elisabetta Melloni, Enrico Zauli, Maurizio Bifulco, Rosanna Martinelli and Annalisa Marcuzzi is used under a CC-BY 4.0 license.

Figure 3.8 (Fig 12) by Marcel Hrubša, Tomáš Siatka, Iveta Nejmanová, Marie Vopršalová, Lenka Kujovská Krčmová, Kateřina Matoušová, Lenka Javorská, Kateřina Macáková, Laura Mercolini, Fernando Remião, Marek Máťuš, Přemysl Mladěnka has been modified (cropped) and is used under a CC-BY 4.0 license.

Figure 3.9 (Fig 1) by Jun Zeng, Wenjing Liu, Bing Liang, Lingyu Shi, Shanbo Yang, Jingsen Meng, Jing Chang, Xiaokun Hu, Renshuai Zhang, and Dongming Xing has been modified (cropped) and is used under a CC-BY 4.0 license.

Figure 3.11 (Fig 1) by Simona Scheggi, Graziano Pinna, Giulia Braccagni, Maria Graziella De Montis and Carla Gambarana is used under a CC-BY 4.0 license.

Figure 4.1 (Fig 5) by Katharina Schreck and Matthias F. Melzig is used under a CC-BY 4.0 license.

Figure 4.2 (Fig 3) by Joanna Michałowska, Ewa Miller-Kasprzak and Paweł Bogdański is used under a CC-BY 4.0 license.

Figure 4.3 (Fig 1) by Ji-Hye Lee and Jaemin Lee is used under a CC-BY 4.0 license.

Figure 4.4 (Fig 1) by Selvaraj Jayaraman, Anitha Roy, Srinivasan Vengadassalapathy, Ramya Sekar, Vishnu Priya Veeraraghavan, Ponnulakshmi Rajagopal, Gayathri Rengasamy, Raktim Mukherjee, Durairaj Sekar and Reji Manjunathan is used under a CC-BY 4.0 license.

Figure 4.5 (Fig 1) by Dariusz Szukiewicz is used under a CC-BY 4.0 license.

Figure 4.6 (Fig 1) by Beatrice Rosetti and Silvia Marchesan is used under a CC-BY 4.0 license.

Figure 4.6 (Fig 2) by Harish Vashisth has been modified (cropped) and is used under a CC-BY 4.0 license.

Figure 4.7 (Fig 4) by Takuo Ogihara, Kenta Mizoi  and Akiko Ishii-Watabe is used under a CC-BY 4.0 license.

Figure 4.8 (Fig 5) by Takuo Ogihara, Kenta Mizoi  and Akiko Ishii-Watabe is used under a CC-BY 4.0 license.

Figure 4.10 (Fig 1) by Ichiro Nojima and Jun Wada is used under a CC-BY 4.0 license.

Figure 4.14 (Fig 2) by Wenwei Wan, Qikai Qin, Linshan Xie, Hanqing Zhang, Fan Wu, Raymond C. Stevens and Yan Liu has been modified (cropped) and is used under a CC-BY 4.0 license.

Figure 4.16 (Fig 1) by Daria M. Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak and Ewa Straburzyńska-Migaj is used under a CC-BY 4.0 license.

Figure 4.19 (Fig 1) by Tapan Behl, Piyush Madaan, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harrasi, Sridevi Chigurupati, Ibrahim Alrashdi and Simona Gabriela Bungau is used under a CC-BY 4.0 license.

Figure 5.1 ( Phospholipases2) by Roadnottaken is used under a CC BY-SA 3.0 license.

Figure 5.3 (Fig 1) by Cándido Ortiz-Placín, Alba Castillejo-Rufo, Matías Estarás and Antonio González is used under a CC-BY 4.0 license.

Figure 5.4 (Fig 1) by Inger L. Meek, Mart A.F.J. Van de Laar and Harald E. Vonkeman is used under a CC-BY 3.0 license.

Figure 6.1 (Fig 1) by Mike P. Williamson is used under a CC-BY 4.0 license.

References

Adcock, D. M., and R. Gosselin. 2015. “Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.” Thrombosis Research 136(1): 7–12.

Ayoub, Samir S. 2021. “Paracetamol (Acetaminophen): A Familiar Drug with an Unexplained Mechanism of Action.” Temperature 8(4): 351–71.

Bailey, Clifford J. 2017. “Metformin: Historical Overview.” Diabetologia 60(9): 1566–76.

Burnett, Allison E. et al. 2016. “Guidance for the Practical Management of the Direct Oral Anticoagulants (DOACs) in VTE Treatment.” Journal of Thrombosis and Thrombolysis 41(1): 206–32.

Cavallari, Larisa H., and Minoli A. Perera. 2012. “The Future of Warfarin Pharmacogenetics in under-Represented Minority Groups.” Future Cardiology 8(4): 563–76.

Cretoiu, Dragos et al. 2021. “Gut Microbiome, Functional Food, Atherosclerosis, and Vascular Calcifications—is There a Missing Link?” Microorganisms 9(9).

Druker, Brian J. 2002. “STI571 (GleevecTM) as a Paradigm for Cancer Therapy.” Trends in Molecular Medicine 8(4 SUPPL.).

Durrington, Paul, and Handrean Soran. 2014. “Hyperlipidemia.” In Metabolism of Human Diseases: Organ Physiology and Pathophysiology, , 295–302.

Endo, A. 1992. “The Discovery and Development of HMG-CoA Reductase Inhibitors.” Journal of Lipid Research 33(11): 1569–82.

Farnier, Michel, and Jean Davignon. 1998. “Current and Future Treatment of Hyperlipidemia: The Role of Statins.” In American Journal of Cardiology, , 3J–10J.

Gage, Brian F., Stephan D. Fihn, and Richard H. White. 2000. “Management and Dosing of Warfarin Therapy.” American Journal of Medicine 109(6): 481–88.

Greinacher, Andreas. 2009. “Heparin-Induced Thrombocytopenia.” Journal of Thrombosis and Haemostasis 7(SUPPL. 1): 9–12.

Grinstein, Jonathan D. 2023. “The Immaculate Conception of Gleevec, As Told by Brian Druker.” Genetic Engineering and Biotechnology News 5(1): 325–28.

Gröber, U., J. Reichrath, M. F. Holick, and K. Kisters. 2014. “Vitamin K: An Old Vitamin in a New Perspective.” Dermato-Endocrinology 6(1).

Guillamat-Prats, Raquel. 2022. “Role of Mesenchymal Stem/Stromal Cells in Coagulation.” International Journal of Molecular Sciences 23(18).

Hemker, H. C. 2016. “A Century of Heparin: Past, Present and Future.” Journal of Thrombosis and Haemostasis 14(12): 2329–38.

Hrubša, Marcel et al. 2022. “Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5.” Nutrients 14(3).

Ivanova, Donika et al. 2018. “Vitamin K: Redox-Modulation, Prevention of Mitochondrial Dysfunction and Anticancer Effect.” Redox Biology 16: 352–58.

Kelton, John G., and Theodore E. Warkentin. 2008. “Heparin-Induced Thrombocytopenia: A Historical Perspective.” Blood 112(7): 2607–16.

Khavandi, Kaivan et al. 2014. “Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression.” Current Vascular Pharmacology 12(1): 155–67.

Kriaa, Aicha et al. 2022. “Bile Acids: Key Players in Inflammatory Bowel Diseases?” Cells 11(5).

Kumano, Osamu, Kohei Akatsuchi, and Jean Amiral. 2021. “Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants.” Biomedicines 9(3).

L, Dean. 2018. “Warfarin Therapy and VKORC1 and CYP Genotype.” Medical Genetics Summaries (Md): 1–9. http://europepmc.org/books/NBK84174%0Ahttps://europepmc.org/article/NBK/nbk84174.

Lampsas, Stamatios et al. 2023. “Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.” Molecules 28(3).

Lee, Catherine J., and Jack E. Ansell. 2011. “Direct Thrombin Inhibitors.” British Journal of Clinical Pharmacology 72(4): 581–92.

Lee, Ji Hye, and Jaemin Lee. 2022. “Endoplasmic Reticulum (ER) Stress and Its Role in Pancreatic β‐Cell Dysfunction and Senescence in Type 2 Diabetes.” International Journal of Molecular Sciences 23(9).

Lee, William M. 2020. “Acetaminophen Toxicity: A History of Serendipity and Unintended Consequences.” Clinical Liver Disease 16(S1): 34–44.

Lin, Yen Lin, Yilin Meng, Wei Jiang, and Benoît Roux. 2013. “Explaining Why Gleevec Is a Specific and Potent Inhibitor of Abl Kinase.” Proceedings of the National Academy of Sciences of the United States of America 110(5): 1664–69.

Lutsey, Pamela L., and Neil A. Zakai. 2023. “Epidemiology and Prevention of Venous Thromboembolism.” Nature Reviews Cardiology 20(4): 248–62.

Martinelli, Ida, Paolo Bucciarelli, and Pier Mannuccio Mannucci. 2010. “Thrombotic Risk Factors: Basic Pathophysiology.” Critical Care Medicine 38(SUPPL. 2).

Meek, Inger L., Mart A.F.J. van de Laar, and Harald E. Vonkeman. 2010. “Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.” Pharmaceuticals 3(7): 2146–62.

Michałowska, Joanna, Ewa Miller-Kasprzak, and Paweł Bogdański. 2021. “Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.” Nutrients 13(2): 1–32.

Mueckler, Mike, and Bernard Thorens. 2013. “The SLC2 (GLUT) Family of Membrane Transporters.” Molecular Aspects of Medicine 34(2–3): 121–38.

Nakamura, M T, and T Y Nara. 2004. “Structure, Function, and Dietary Regulation of delta6, delta5, and delta9 Desaturases.” Annu Rev Nutr 24: 345–76.

Nawarskas, James J. 2005. “HMG-CoA Reductase Inhibitors and Coenzyme Q10.” Cardiology in Review 13(2): 76–79.

Nojima, Ichiro, and Jun Wada. 2023. “Metformin and Its Immune-Mediated Effects in Various Diseases.” International Journal of Molecular Sciences 24(1).

Ogihara, Takuo, Kenta Mizoi, and Akiko Ishii-Watabe. 2023. “Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design.” Biomedicines 11(5).

Ortel, Thomas L. et al. 2020. “American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism.” Blood Advances 4(19): 4693–4738.

Ortiz-Placín, Cándido, Alba Castillejo-Rufo, Matías Estarás, and Antonio González. 2023. “Membrane Lipid Derivatives: Roles of Arachidonic Acid and Its Metabolites in Pancreatic Physiology and Pathophysiology.” Molecules 28(11).

Phan, Binh An P., Thomas D. Dayspring, and Peter P. Toth. 2012. “Ezetimibe Therapy: Mechanism of Action and Clinical Update.” Vascular Health and Risk Management 8(1): 415–27.

Pisanti, Simona et al. 2022. “Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation.” International Journal of Environmental Research and Public Health 19(15).

Porter, William R. 2010. “Warfarin: History, Tautomerism and Activity.” Journal of Computer-Aided Molecular Design 24(6–7): 553–73.

Rieg, Timo, and Volker Vallon. 2018. “Development of SGLT1 and SGLT2 Inhibitors.” Diabetologia 61(10): 2079–86.

Rosetti, Beatrice, and Silvia Marchesan. 2023. “Peptide Inhibitors of Insulin Fibrillation: Current and Future Challenges.” International Journal of Molecular Sciences 24(2).

Scheggi, Simona et al. 2022. “PPARα Signaling: A Candidate Target in Psychiatric Disorder Management.” Biomolecules 12(5).

Schreck, Katharina, and Matthias F. Melzig. 2018. “Intestinal Saturated Long-Chain Fatty Acid, Glucose and Fructose Transporters and Their Inhibition by Natural Plant Extracts in Caco-2 Cells.” Molecules 23(10).

Smith, Francine G., Andrew W. Wade, Megan L. Lewis, and Wei Qi. 2012. “Cyclooxygenase (COX) Inhibitors and the Newborn Kidney.” Pharmaceuticals 5(11): 1160–76.

Staels, Bart et al. 1998. “Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism.” Circulation 98(19): 2088–93.

Szukiewicz, Dariusz. 2023. “Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity.” International Journal of Molecular Sciences 24(12).

Tada, Hayato, Atsushi Nohara, and Masa Aki Kawashiri. 2018. “Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies.” Nutrients 10(11).

Tobert, Jonathan A. 2003. “Lovastatin and beyond: The History of the HMG-CoA Reductase Inhibitors.” Nature Reviews Drug Discovery 2(7): 517–26.

Turunen, Mikael, Jerker Olsson, and Gustav Dallner. 2004. “Metabolism and Function of Coenzyme Q.” Biochimica et Biophysica Acta – Biomembranes 1660(1–2): 171–99.

Vashisth, Harish. 2015. “Theoretical and Computational Studies of Peptides and Receptors of the Insulin Family.” Membranes 5(1): 48–83.

Vaz, JuliusA, and Ashis Patnaik. 2012. “Diabetes Mellitus: Exploring the Challenges in the Drug Development Process.” Perspectives in Clinical Research 3(3): 109.

Wan, Wenwei et al. 2023. “GLP-1R Signaling and Functional Molecules in Incretin Therapy.” Molecules 28(2).

Wardrop, Douglas, and David Keeling. 2008. “The Story of the Discovery of Heparin and Warfarin.” British Journal of Haematology 141(6): 757–63.

Williamson, Mike P. 2023. “Protein Binding: A Fuzzy Concept.” Life 13(4).

Zeng, Jun et al. 2022. “Inhibitory Effect of Isoliquiritigenin in Niemann-Pick C1-Like 1-Mediated Cholesterol Uptake.” Molecules 27(21).

Zhao, Yanfang et al. 2015. “Design, Synthesis and Structure – Activity Relationship of Oxazolidinone Derivatives Containing Novel S4 Ligand as FXa Inhibitors.” European Journal of Medicinal Chemistry 96: 369–80.

Cover Image

The image used on the cover is “Dispensing cell culture media” by Bilal Saqib (CC BY-NC-SA)